Natera, Inc. (NASDAQ:NTRA) Given Consensus Rating of “Buy” by Analysts

Shares of Natera, Inc. (NASDAQ:NTRA) have received an average recommendation of “Buy” from the fourteen brokerages that are presently covering the stock, MarketBeat.com reports. Fourteen research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued a report on the stock in the last year is $86.40.

A number of equities research analysts recently commented on NTRA shares. Stephens reiterated an “overweight” rating and set a $78.00 price target on shares of Natera in a report on Tuesday, January 30th. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective on the stock in a research report on Friday, April 5th. Piper Sandler boosted their price objective on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Canaccord Genuity Group boosted their price objective on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, Craig Hallum began coverage on shares of Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 price objective on the stock.

Insider Activity at Natera

In other news, insider Jonathan Sheena sold 6,000 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $70.00, for a total value of $420,000.00. Following the sale, the insider now directly owns 18,155 shares of the company’s stock, valued at $1,270,850. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Daniel Rabinowitz sold 35,307 shares of Natera stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $75.09, for a total value of $2,651,202.63. Following the completion of the transaction, the insider now owns 204,218 shares of the company’s stock, valued at approximately $15,334,729.62. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jonathan Sheena sold 6,000 shares of Natera stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $70.00, for a total value of $420,000.00. Following the completion of the transaction, the insider now directly owns 18,155 shares of the company’s stock, valued at approximately $1,270,850. The disclosure for this sale can be found here. Insiders sold a total of 434,943 shares of company stock valued at $35,419,396 in the last 90 days. Corporate insiders own 9.42% of the company’s stock.

Hedge Funds Weigh In On Natera

Several large investors have recently modified their holdings of the stock. Arcadia Investment Management Corp MI increased its holdings in Natera by 47.8% in the 1st quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after buying an additional 174 shares in the last quarter. Fifth Third Bancorp increased its holdings in Natera by 3.0% in the 4th quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after buying an additional 179 shares in the last quarter. Treasurer of the State of North Carolina increased its holdings in Natera by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 45,469 shares of the medical research company’s stock worth $2,012,000 after buying an additional 230 shares in the last quarter. Xponance Inc. increased its holdings in Natera by 1.8% in the 3rd quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock worth $642,000 after buying an additional 261 shares in the last quarter. Finally, Oliver Lagore Vanvalin Investment Group increased its holdings in Natera by 109.3% in the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after buying an additional 389 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

NASDAQ:NTRA opened at $94.04 on Tuesday. The company has a fifty day moving average of $88.64 and a 200 day moving average of $68.20. Natera has a 52 week low of $36.90 and a 52 week high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The company had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. On average, equities research analysts predict that Natera will post -2.35 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.